Skip to content
lifestyle.cosmeticsurgeryinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Alvotech
Alvotech to Report Financial Results for H1 2026
August 10, 2026
Alvotech announces successful closure of FDA inspection of manufacturing facility
July 29, 2026
Alvotech further strengthens liquidity by securing term loan facility of $75 million
July 1, 2026
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
June 18, 2026
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
June 18, 2026
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
June 16, 2026
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
June 15, 2026
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
June 4, 2026
Main Results of 2026 Annual and Extraordinary General Meeting
June 3, 2026
Alvotech to present at upcoming investor conferences in June
June 2, 2026
1
2
Next Page
→